Category: 8. Health

  • Plant-based omega-3s offer similar benefits to marine-derived iterations, review notes

    Plant-based omega-3s offer similar benefits to marine-derived iterations, review notes


    A new review published in Lipids has highlighted the potential of plant-based omega-3 oils in promoting gut health.1


    The article delves into how omega-3 oils rich in stearidonic acid (SDA) can influence the microbiome, promote optimal gut barrier function, help mitigate systemic inflammation and boost overall wellness.


    Published by researchers from the University of Southampton, the piece also explores the rising interest in plant-based omega-3 sources.


    According to Baker et al., this trend is primarily driven by the increased  intrigue towards both ethical and sustainable dietary choices — with many now turning away from fish oil products in favour of more environmentally-friendly options. 


    The review covers: 


    • How very long chain polyunsaturated fatty acids (VLF-PUFAs) present in plant-based extracts can balance the gut microbiome 
    • How VLF-PUFAs exhibit a prebiotic effect within the gut 
    • The potential of SDA-rich oils in mitigating inflammation as well as promoting gut barrier and immune function
    • How SDA oils modulate the gut-brain/gut-liver axes
    • How users can gain similar omega-3-related health and wellness benefits from plant-based sources compared with traditional fish oil
    • Why plant-based omega-3s are more sustainable than traditional fish oils


    Notably, the researchers tout the benefits of Nature Crops International’s branded Ahiflower oil, which is derived from Buglossoides arvensis.


    Oil from this particular botanical species is rich in SDA, which promotes efficient omega-3 EPA conversion and DHA formation in the liver and brain; despite its inability to raise DHA levels in the red blood cells.


    This suggests that the beneficial fatty acids produces are being metabolised and used by the body more efficiently, according to Baker.


    “As we uncover the power of omega-3s in promoting cardiovascular, gut, skin, immune-inflammatory and mental health, there will continue to be an increase in demand for these products — creating an unsustainable supply chain if we were to rely solely on marine sources,” she says.


    “To overcome this issue, it’s crucial to embrace plant-based omega-3 options — which are demonstrably beneficial for all these health goals.”


    “Ahiflower oil is one of nature’s richest sources of omega-3, and this newly published research only further underscores its key role in overall wellness. By choosing a clean-label, regeneratively farmed omega-3 solution, supplement manufacturers can not only enhance the benefits of their product, but also choose a sustainable option,” Baker concludes.


     


    Reference 


    1  https://pubmed.ncbi.nlm.nih.gov/40574533/#:~:text=Recent%20studies%20highlight%20the%20efficient,distinct%20SDA%2Dderived%20metabolites).


     



      

    Continue Reading

  • New Weight-Loss Drugs Under Scrutiny Amid Pancreas Concerns : ScienceAlert

    New Weight-Loss Drugs Under Scrutiny Amid Pancreas Concerns : ScienceAlert

    Popular weight-loss drugs like Ozempic and Zepbound have revolutionized how we tackle obesity. But now, emerging reports about potential side effects have prompted a new investigation by UK health regulators.

    Hundreds of people reported experiencing severe pancreas problems after taking these drugs, according to the BBC.

    The UK government is now asking anyone who’s been affected to contact them. They are particularly interested in understanding whether genetic factors may predispose certain individuals to such severe reactions.

    As always with health alerts, it’s crucial to put this news into perspective. There’s no clear evidence yet that these drugs are directly causing pancreas damage. Their known side effects are already well-documented and they remain approved as safe for use when prescribed and overseen by a doctor.

    Related: Ozempic Alternative Ditches The Needle And One Major Side Effect

    And that last part – doctor oversight – is vital: it’s not safe to obtain these drugs through unofficial channels. Even if you can be sure you’re getting what you asked for – which you can’t – these medications aren’t right for everyone.

    It’s important to note that when any medication is taken up by a large number of people, it will inevitably reach some who will experience health issues regardless of the drugs they’re on, and rare adverse reactions will likely also occur.

    But the sheer number of reports of acute or chronic pancreatitis warrants further examination, and the cases so far involve up to 10 fatalities. The investigation is being managed by the Medicines and Healthcare products Regulatory Agency and Genomics England.

    Collectively, the drugs being looked at are known as GPL-1 (glucagon-like peptide-1) receptor agonists, because they target cells in the body usually activated by the natural GLP-1 hormone, which controls blood sugar and appetite – hence why they’re used for diabetes and weight loss.

    Issues have been reported with pancreas conditions. (Sebastian Kaulitzki/Science Photo Library/Getty Images)

    These medications can be split into two types: those based on semaglutide (such as Ozempic and Wegovy), and those based on tirzepatide (including Mounjaro and Zepbound). The latter type also targets glucose-dependent insulinotropic polypeptide (GIP) receptors, as well as GLP-1 receptors, for a stronger effect.

    To date, almost 400 reports of acute pancreatitis have been received from people using GLP-1 drugs such as Mounjaro, Wegovy, Ozempic, and liraglutide, as per The Guardian. Nearly half of those, 181, involve the tirzepatide-based drug sold as Mounjaro.

    Genetic risk is one of the factors being studied, which may mean some people are more prone to pancreatic issues. In the case of acute or chronic pancreatitis, this manifests itself as severe stomach pain that won’t go away.

    Those in the UK aged over 18, who have a strong adverse reaction to one of these weight loss and diabetes drugs are being asked to register their details on the Yellow Card website (the official UK system for reporting issues with approved medications).

    From there, you’ll be asked to submit more information and a saliva sample, if you’re chosen to take part in a study of GLP-1 drugs and pancreatic issues.

    The effects of all medications have to be considered in relation to other factors, including existing health conditions, genetics, age, and sex. Even the most effective drugs can come with risks.

    “GLP-1 medicines like Ozempic and Wegovy have been making headlines, but like all medicines there can be a risk of serious side effects,” says geneticist Matt Brown from Genomics England.

    “We believe there is real potential to minimize these, with many adverse reactions having a genetic cause.”

    Continue Reading

  • WHO donates medical supplies and equipment to boost mpox response | WHO

    Freetown, Sierra Leone – As part of its continued support to Sierra Leone’s health sector, the World Health Organization (WHO) has donated essential medical supplies, mpox test kits, and laboratory equipment, including five medical-grade refrigerators valued at over USD 126,000 to the Ministry of Health.

    The handover ceremony took place at the Hastings Treatment Centre, with WHO Country Representative Dr George Ameh officially handing over the supplies to Deputy Chief Medical Officer Dr Mustapha Kabba.

    The donation comes at a critical time as the country continues to respond to the ongoing mpox outbreak, with over 4,000 confirmed cases to date. The supplies will strengthen diagnostic and case management capacity at key treatment and testing sites: Lakka Hospital, Benguema Reference Laboratory, and Hastings Treatment Centre.

    “Our support today reflects WHO’s commitment to ensuring that frontline health workers have the tools they need to manage cases effectively and reduce transmission,” said Dr George Ameh, WHO Representative in Sierra Leone. “These supplies will help improve the quality of care and expand diagnostic capabilities at a time when rapid response remains crucial.”

    Receiving the supplies, Deputy Chief Medical Officer Dr Mustapha Kabba expressed deep appreciation for WHO’s ongoing support and used the occasion to commend frontline healthcare workers at Hastings.

    “We are sincerely grateful to WHO for their continued and timely support throughout this mpox response,” said Dr Kabba. “I want to encourage the hardworking team at Hastings Treatment Centre to continue the work. Your dedication is making a real difference, and we thank you for your tireless efforts in protecting the health of our communities.”

    The Hastings Treatment Centre, one of the designated facilities for mpox case management, is expected to receive a share of the supplies and equipment, which will be used to bolster patient care and improve cold chain storage for samples and medicines.

    “With these additional resources, we can ensure better storage of lab reagents, enhance patient care, and maintain the quality of our services,” said Dr Darlinda Jiba, the facility In-charge at Hastings Treatment Centre. “WHO’s continued support is a true morale booster for our clinical teams.”

    The support is part of WHO’s continued commitment to strengthening Sierra Leone’s health system and response capacity.

    Continue Reading

  • Five factors beyond sperm count that cause male infertility

    Five factors beyond sperm count that cause male infertility

    The latest report on global fertility by the United Nations Population Fund (UNFPA) says infertility is a key barrier to reproductive autonomy for almost 13 per cent of Indians. Studies also show that among the approximately 28 million people in the country who face infertility, male-factor infertility accounts for 40-50 per cent of the cases.

    Despite such a significant proportion, male fertility remains under-discussed and underdiagnosed, with little to no awareness beyond sperm count. This leaves no room to acknowledge the complex causes and possible solutions to the condition. Dr Vaani Mehta, fertility specialist at Birla Fertility and IVF, Chandigarh, lists the lesser-known factors impacting male fertility:

    Genetics: Genetic abnormalities are often left out of discussions when talking about infertility even though they can be significant contributors. One such example would be microdeletions in the Y chromosome, particularly in the Azoospermia Factor or AzF gene. If any part of AzF is deleted or mutated, it can disrupt the entire process of spermatogenesis and lead to a severely low sperm count or even complete absence of sperm in semen, resulting in infertility.

    Sexual dysfunction: Sexual dysfunction that affects fertility can manifest in many ways, with symptoms such as erectile dysfunction, problems relating to ejaculation and even low libido. In a 2023 study by the American Society for Reproductive Medicine, a projected 322 million men around the world were to be impacted by sexual dysfunction in 2025. Despite its impact, male sexual dysfunction is often underdiagnosed or undertreated. Recognising such symptoms early and addressing them through medical, psychological or lifestyle changes can significantly improve chances of natural conception.

    Unhealthy lifestyle: Unhealthy lifestyle is another big factor that impacts male infertility. Several factors, such as obesity, diet or nutrition, stress, smoking and alcohol use, affect not just sperm count but also motility, morphology and sperm DNA.

    Stress and emotional wellbeing: Our societal construct pressures men to curb their emotions, which leads to underlying stress and loneliness. Couple this with the stress and pressure to conceive and it negatively impacts their emotional health. It is essential for men and couples to put emotional wellbeing in focus and regulate stress to ease their fertility journey.

    Comorbidities: Underlying health issues, such as diabetes and hypertension, can also have a major impact on male fertility. High blood sugar levels can reduce sperm mobility, damage sperm DNA and hamper sperm morphology. Similarly, hypertension can affect blood flow to reproductive organs and even impact hormone regulation.

    Subscribe to India Today Magazine

    – Ends

    Published By:

    Shyam Balasubramanian

    Published On:

    Jul 3, 2025

    Continue Reading

  • Wernicke encephalopathy in pregnancy associated with hyperemesis gravidarum: a case report | BMC Pregnancy and Childbirth

    Wernicke encephalopathy in pregnancy associated with hyperemesis gravidarum: a case report | BMC Pregnancy and Childbirth

    Hyperemesis gravidarum (HG) is a severe form of nausea and vomiting in pregnancy that can lead to significant maternal and fetal morbidity. One of the rare but serious complications of HG is Wernicke Encephalopathy (WE), a neurological, potentially life-threatening condition caused by thiamine deficiency, which is essential for glucose metabolism [15].

    It is known that human neurons account for only 10% of brain cells, but are responsible for as much as 90% of glucose consumption in the brain. Since glucose is the main source of energy for neurons, thiamine deficiency impairs the utilisation of glucose as a substrate for neuronal energy metabolism, resulting in selective neuronal death. This causes oxidative stress, reduced ATP production, glutamate excitotoxicity, inflammation, lactic acidosis, impaired astrocyte function, and decreased neurogenesis — resulting in metabolic imbalance and neurological complications [16]. In the absence of supplementation, thiamine deficiency can develop within 2 to 3 weeks. Early manifestations of WE may include nonspecific symptoms such as fatigue, memory impairment, sleep disturbances, and emotional lability. The classic clinical triad of ataxia, ophthalmoplegia, and altered mental status is only present in 16–20% of patients at initial evaluation, which further complicates timely diagnosis [15]. The diagnosis of WE remains based on clinical symptoms. There are no rapid, routine diagnostic tests for this condition. Blood thiamine levels can be measured, but there is no established threshold level that would be safe for patients before brain damage develops. Magnetic resonance imaging has high specificity but poor (53%) sensitivity and can therefore only confirm clinical suspicion of WE [16]. Non-specific clinical symptoms and rare occurrence make it difficult to diagnose WE, especially in pregnant women. The association between WE and hyperemesis gravidarum is well documented, therefore, caregivers of pregnant women must consider WE and treat this condition immediately in women reporting severe vomiting and inability to eat, as two to three weeks of unbalanced nutrition can lead to thiamine depletion and life-threatening complications. Awareness of possible predisposing factors and maintaining a high level of clinical suspicion are the best tools for early diagnosis, which is crucial for preventing neurological sequelae [17]. Prevalence data on Wernicke encephalopathy (WE) comes primarily from autopsy studies, which report rates ranging between 1% and 3%. Several studies have shown that clinical records tend to underestimate the true prevalence, as the diagnosis is often overlooked or missed. The incidence of WE is thought to be higher in developing countries, largely due to widespread vitamin deficiencies and malnutrition [15]. In the context of HG, thiamine deficiency is primarily related to insufficient intake and impaired absorption due to persistent nausea and vomiting, as well as the increased metabolic demands of the growing fetus and the hypermetabolic state of pregnancy [17].

    Persistent vomiting in hyperemesis gravidarum significantly contributes to thiamine depletion, particularly in pregnancy, where maternal demands are elevated. Women with hyperemesis gravidarum (HG) are frequently dehydrated and suffer from significant weight loss, malnutrition, electrolyte imbalances, and vitamin deficiencies [17]. Malnutrition associated with WE in pregnancy is a rare but serious and preventable consequence of hyperemesis gravidarum, which requires attention due to its rapid onset and unfavourable course. Unfortunately, as reported by the authors of a systematic review, symptoms of WE are currently often overlooked or exacerbated by the administration of glucose, leading to poorer outcomes for the mother and foetus, which could have been avoided by the prophylactic administration of thiamine injections [2]. In our case, glucose-containing fluids were administered before thiamine supplementation as part of routine intravenous therapy for vomiting, at a time when thiamine deficiency had not yet been suspected. It is therefore possible that this contributed to the clinical manifestation of WE. This underscores the importance of empirical thiamine supplementation in pregnant patients at risk of deficiency, especially before administering glucose-containing fluids. Similar risks are observed in patients undergoing cancer treatment, where chemotherapy-induced nausea and poor intake can also lead to severe nutritional deficiencies. Other risk factors include bariatric surgery, prolonged intravenous nutrition without adequate supplementation, chronic hemodialysis, and magnesium depletion [9, 18]. Given that magnesium is a cofactor for thiamine-dependent enzymes, its deficiency can further impair thiamine utilization, increasing the risk of neurological complications. Diets high in carbohydrates or containing thiaminase-rich foods further heighten the risk. Moreover, chronic alcohol use, restrictive diets, or food consumption with thiamine antagonists are linked to impaired utilization of this essential nutrient. These complex interactions underline the multifactorial etiology of thiamine deficiency, which, if unresolved, may progress to severe neurological conditions such as WE and even further to Wernicke-Korsakoff syndrome (WKS). Although Wernicke Encephalopathy is classically associated with chronic alcohol use, recent evidence highlights its occurrence in various non-alcoholic contexts. Chamorro et al. demonstrated that non-alcoholic WE may differ in clinical presentation and is frequently underdiagnosed due to atypical or subtle symptomatology [19]. Moreover, Koca et al. reported a case of WE in a patient with cholangiocellular carcinoma, illustrating how persistent vomiting and malnutrition, even in the absence of alcohol use, can precipitate severe thiamine deficiency [20]. These findings align with our case and emphasize the need for heightened awareness and early intervention in at-risk non-alcoholic populations, particularly in pregnancy and oncology settings.

    To address prolonged or severe nausea and vomiting in pregnancy, particularly in cases persisting beyond the first trimester, early screening for complications and timely intervention are needed in women. Identifying and addressing nutritional deficiencies, especially thiamine deficiency, should be a priority for midwives and women’s health providers [8, 9, 21]. This is crucial for preventing complications such as WE [21].

    The use of a validated, clinically practical, and easy to use tool that measures severity of NVP, such as the Pregnancy-Unique Quantification of Emesis and Nausea (PUQE) scoring system (PUQE-12 or PUQE-24), can assist with monitoring progression and treatment. The PUQE scoring system is a validated tool for assessing the severity of NVP and can help guide management decisions. Despite its utility, it is not consistently applied in practice, potentially delaying recognition of severe cases [11]. In addition to PUQE scores, clinicians should be aware of red flag symptoms that warrant urgent intervention, such as persistent ketonuria, signs of dehydration, significant weight loss, electrolyte imbalances, altered mental status, or any neurological symptoms suggestive of thiamine deficiency.

    Currently, there are no universally accepted guidelines specifying exact blood thiamine levels that should trigger therapeutic intervention. Given this, clinical decision-making should prioritize early recognition of symptoms and implementation of preventative strategies, rather than relying solely on laboratory-confirmed deficiency [22]. Reference values may vary between laboratories, and the interpretation of results should take into account the patient’s clinical status and symptoms suggestive of thiamine deficiency. In cases where thiamine deficiency is suspected, such as in hyperemesis gravidarum, chronic malnutrition, prolonged parenteral nutrition, or alcohol use disorder, early administration of high-dose thiamine is recommended, even before laboratory confirmation. While thiamine deficiency is typically defined as a blood thiamine level below 28 µg/L (2.1 nmol/L), a severe deficiency requiring urgent intervention is generally considered when levels fall below 7 µg/L (0.5 nmol/L) [11, 12, 22]. However, the presence of neurological symptoms consistent with WE (ophthalmoplegia, ataxia, confusion) should prompt immediate administration of 500 mg IV (intravenous) thiamine every 8 h for 3 days, followed by 250 mg IV daily for 5 additional days, in accordance with recent clinical guidelines [6, 9, 11, 12]. The presence of neurological symptoms is emphasized in the diagnostic criteria for Wernicke encephalopathy, as decreased thiamine levels alone is insufficient to establish the diagnosis [14]. Given the potentially irreversible neurological damage associated with thiamine deficiency, particularly in high-risk populations, preventive supplementation (oral 100 mg tds or intravenous as part of vitamin B complex) should be considered in individuals with prolonged vomiting, severe malnutrition, or other conditions predisposing to tiamine depletion [11]. Although there are recommendations for the treatment of Wernicke encephalopathy, they are not specifically tailored to pregnant women. Existing guidelines for pregnant women in the context of hyperemesis gravidarum (HG) mainly focus on the prevention of WE. There are some case reports of WE in pregnancy with various doses of thiamine administered (ranging from 100 to 500 mg a day orally or intravenously) [9].

    In instances where standard dietary and lifestyle measures fail to control symptoms, timely pharmacological intervention may be warranted. Pharmacological antiemetic therapy is still used with great caution by some patients and health care providers to treat NVP and is erroneously considered to be contraindicated in pregnancy [23]. However, substantial evidence supports the safety and efficacy of specific antiemetics, such as pyridoxine-doxylamine, antihistamines (e.g. diphenhydramine, meclizine), phenothiazines (e.g. promethazine), and ondansetron, when used appropriately.

    Beyond pharmacological management, dietary and lifestyle modifications play a significant role in alleviating symptoms. Encouraging patients to consume small, frequent meals with an emphasis on protein rather than fats and carbohydrates while avoiding strong odors, greasy foods, and overly sweet items can help reduce nausea [24, 25]. Proper hydration strategies should also be emphasized, including separating liquid intake from solid meals to minimize gastrointestinal discomfort [26]. For women requiring intravenous hydration, normal saline (0.9% NaCl) with added potassium chloride is recommended, with administration guided by daily electrolyte monitoring. In cases where a single antiemetic is ineffective, a combination of agents should be considered.

    Before considering termination of pregnancy, all possible therapeutic measures should be explored to ensure optimal management of severe NVP and HG. This includes the use of corticosteroids in treatment-resistant cases, as recommended by clinical guidelines, given their potential efficacy when other options have failed.

    Early recognition and timely intervention in Hyperemesis Gravidarum (HG) are crucial for preventing weight loss, general weakness, and recurrent hospitalizations. Comprehensive treatment should include medical management, patient education, dietary and lifestyle modifications, and emotional support. Such an approach not only improves maternal health and quality of life during pregnancy but also reduces the need for parenteral therapy, alleviating both the financial and emotional burden on families and the healthcare system [4, 10, 21].

    There is limited evidence suggesting that pregnant women with HG often found interactions with healthcare professionals challenging, with many reporting that their concerns were dismissed and that the complications of HG were downplayed [27]. In response to these challenges, Irish researchers have strongly advocated for the establishment of dedicated HG clinics. This type of service is an example of both individualized and multidisciplinary care. These interdisciplinary services offer comprehensive care, treatment, and support from midwives, dietitians, obstetricians, and mental health specialists. Patients attending these clinics receive an individualized assessment from a dietitian at each visit, with specialists determining the necessity of intravenous (IV) fluid therapy and vitamin supplementation, as well as reviewing or adjusting medication doses. As concluded in the study, dedicated multi-disciplinary HG clinics, available nationally and internationally for all women with HG, are strongly recommended [28].

    Severe HG when left unmanaged, can progress to serious complications, including WE, necessitating a coordinated, interdisciplinary approach to patient care. This collaboration involves obstetricians, midwives, neurologists, psychiatrists, addiction specialists, dietitians, and social workers, each contributing their expertise to address the multifaceted needs of affected patients [29].

    Midwives and obstetricians are often the first to detect signs of excessive vomiting and associated nutritional deficiencies during pregnancy. Their role includes monitoring for symptoms such as severe dehydration, weight loss, and neurological changes that could indicate the development of WE. Educating healthcare providers on the early neurological signs of thiamine deficiency, beyond the classical triad of WE, is essential to prevent delayed diagnosis. Early referral to neurologists is essential for assessing and managing potential cognitive or motor impairments resulting from thiamine deficiency that are a hallmark of WE [21, 23, 30].

    In cases where hyperemesis may be linked to alcohol misuse, psychiatrists and addiction specialists are vital for evaluating and treating underlying dependency issues [30,31,32]. Comorbid psychiatric conditions, such as anxiety and depression, are common in HG and require integrated mental health support. This includes addressing the psychosocial challenges that may exacerbate the condition, such as stress, anxiety, or inadequate social support. Dietitians play a crucial role in monitoring and addressing nutritional deficits, ensuring adequate thiamine supplementation, and providing dietary strategies to minimize symptoms of HG [33, 34].

    Social workers complete the interdisciplinary framework by assessing the patient’s broader circumstances, including access to food, housing stability, and overall well-being. They can facilitate interventions when social determinants of health, such as financial hardship or unsafe living conditions, hinder recovery.

    Our case highlights the importance of early identification and treatment of thiamine deficiency in pregnant patients with hyperemesis gravidarum to prevent irreversible neurological damage. Understanding the risk factors, the need for screening and early intervention, and algorithmic management of treatment is crucial. When considering the evidence from our case report alongside findings from the literature, it becomes evident that a comprehensive, multidisciplinary approach not only enhances maternal outcomes but also protects fetal development. This underscores the importance of early detection, holistic care, and coordinated efforts among healthcare providers to prevent severe complications associated with thiamine deficiency [29].

    Continue Reading

  • IDSA Experts Weigh Potential Vaccine Access Impact

    IDSA Experts Weigh Potential Vaccine Access Impact

    Vaccine access and uptake will be affected by the recent actions of the Centers for Disease Control and Prevention’s (CDC’s) Advisory Committee on Immunization Practices (ACIP), but the extent remains unclear, according to experts in a press briefing sponsored by the Infectious Diseases Society of America (IDSA).

    “I watched with absolute horror as the 17 members of ACIP were summarily fired and replaced with seven members who had limited expertise [in relevant areas],” Andrew T. Pavia, MD, Chief of the Division of Pediatric Infectious Diseases at University of Utah Health, Salt Lake City, Utah, said in the briefing.

    Vaccines aren’t perfect, but one of the fundamental benefits of a functional ACIP is that physicians can watch the deliberations take place and look at the same data that ACIP has reviewed in making recommendations, he said. Without the careful review and debate of evidence, insurers and clinicians alike face uncertainty, he said.

    Fortunately, ACIP voted to recommend a second monoclonal antibody for prevention of respiratory syncytial virus in infants and recommended that the second product would be added to the Vaccines for Children program, which provides vaccines to approximately half of all children in the United States, Pavia noted.

    Lack of Vote Adds to Uncertainty

    Despite much time dedicated to discussion of COVID-19, no vote occurred with recommendations for vaccination for the coming season, said Angela Branche, MD, associate professor of medicine and infectious diseases specialist and researcher at the University of Rochester, Rochester, New York, in the briefing. Despite evidence presented by CDC experts that young children and pregnant women remain at risk, the lack of a vote leaves clinicians “operating blind for the coming season as to what to do,” she said.

    Although ACIP recommended universal flu vaccination, the accompanying restrictions on use of multi-dose vials for flu vaccine may pose access challenges, especially in rural and underserved communities, said Branche.

    Community clinics in these areas are often pop-ups, and vaccine campaigns tend to be brief, Branche said in the press conference. The use of the now-recommended single-dose flu vaccine vials may be impractical because of the expense of storage and material needed for single-dose injections, she said. Consequently, in terms of vaccine access, communities that are already disadvantaged may be even more so, she emphasized.

    More Questions as Fall Approaches

    The reconstituted ACIP also stated intentions to revisit the current recommended childhood vaccine schedule, which could reduce vaccine access for children across the United States, Pavia said. Regarding the current schedule, “there is no evidence that we are giving too many vaccines to children or too many vaccines close together,” he said in the briefing.

    If ACIP decided to eliminate any recommended vaccinations from the schedule, the implications are unclear, but insurers might no longer cover them and clinicians might be less inclined to promote them, Pavia said.

    Currently, vaccine infrastructure of the United States includes nonpartisan, expert review of the science and the clinical recommendations for each vaccine, and many insurers look to ACIP for guidance on coverage, he added.

    The presenters had no relevant financial conflicts to disclose.

    Continue Reading

  • Low-intensity brain stimulation can restore neuron health in Alzheimer’s disease

    03 Jul 2025

    Researchers in Australia study effects of transcranial magnetic stimulation in mouse models of debilitating illness.

    Alzheimer’s disease (AD) is a debilitating neurodegenerative condition that affects a significant proportion of older people worldwide. Synapses are points of communication between neural cells that are malleable to change based on our experiences. By adding, removing, strengthening, or weakening synaptic contacts, our brain encodes new events or forgets previous ones.

    In AD, synaptic plasticity, the brain’s ability to regulate the strength of synaptic connections between neurons, is significantly disrupted. This worsens over time, reducing cognitive and memory functions leading to reduced quality of life. To date, there is no effective cure for AD, and only limited treatments for managing the symptoms.

    Studies have shown that repetitive transcranial magnetic stimulation (rTMS), a noninvasive brain stimulation technique that uses electromagnetic pulses to target specific brain regions, has therapeutic potential to manage dementia and related diseases.

    From previous studies, we know that rTMS can promote synaptic plasticity in healthy nervous systems. Moreover, it is already used to treat certain neurodegenerative and neuropsychiatric conditions. However, individual responses to rTMS for AD management are variable, and the underlying mechanisms are not clearly understood.

    Recently, researchers from the University of Queensland, Australia, and the Wicking Dementia Research and Education Centre at the University of Tasmania investigated the effects of rTMS on synapses in the brain cortex of mice with Alzheimer’s type dementia. Their report is published in Neurophotonics.

    “Since synaptic dysfunction is a key mechanism in AD, in this study, we quantified the changes in synaptic axonal boutons in AD mouse model in response to rTMS, comparing them to those in healthy mice,” commented corresponding author Dr. Barbora Fulopova, a professor at University of Queensland.

    Profound effects on brain connectivity

    Axonal boutons are specialized endings of an axon, which is the long slender part of a neuron that connects neurons by transmitting neural signals. These are sites where synapses form, allowing neurons to communicate. Therefore, any change in the number or function of these boutons can have profound effects on brain connectivity.

    In this study, the researchers observed structural changes of two types of excitatory boutons, namely “terminaux boutons” (TBs) (short protrusions from the axon shaft typically connecting neurons in a local area) and “en passant boutons” (EPBs) (small bead-like structures along axons typically connecting distal regions). They used two-photon imaging to visualize individual axons and synapses in the brain of a live animal. The study was conducted on the APP/PS1 xThy-1GFP-M strain of mice, which is a cross between the APP/PS1 strain (genetically modified to show AD-like symptoms seen in humans) and the Thy1-GFP-M strain, which expresses a fluorescent protein in certain neurons.

    This combination causes axons to glow during imaging, enabling precise tracking of synaptic bouton changes over time. The team monitored the dynamics of the axonal boutons in these mice at 48-hour intervals for eight days, both before and after a single rTMS session. They then compared these findings to healthy wild-type (WT) mice. They found that both TBs and EPBs in the AD mouse model had comparable density to those in healthy WT mice. However, the turnover of both bouton types was significantly lower in the AD mouse model before rTMS, likely due to the amyloid plaque buildup, a key marker of dementia, and potentially causing diseases like AD.

    After a single session of low-intensity rTMS, the turnover of TBs in both strains increased significantly, while there was no change in the EPB turnover. Notably, the largest changes were observed two days after stimulation with an 88 percent increase in TB turnover for the WT strain and a 213 percent increase in the APP-GFP strain. However, this increase returned to pre-stimulation levels by the eighth day.

    Furthermore, in the AD mouse model, this increased turnover was comparable to the turnover levels in the WT mice seen before stimulation. This indicates that low-intensity rTMS can potentially restore the synaptic plasticity of TBs to those seen in healthy mice. Moreover, the fact that only TBs, and not EPBs, responded to rTMS points to the possibility that the mechanisms of rTMS might be cell-type specific.

    “This is the first study to provide evidence of pre-synaptic boutons responding to rTMS in a healthy nervous system as well as a nervous system marked by the presence of dementia,” said Fulopova. “Given the established link between synaptic dysfunction and cognitive decline in dementia and the use of rTMS for the treatment of other neurodegenerative conditions, our findings highlight its potential as a powerful addition to currently used AD management strategies.”

    This study marks a significant step forward in understanding AD. While further research is required, the findings of this study pave the way for targeted rTMS treatments that could improve the quality of life of patients with Alzheimer’s disease.

    • This article was first published on spie.org.

    Continue Reading

  • Why the Shingles Vax Is Important for Your Cardio Patients

    Why the Shingles Vax Is Important for Your Cardio Patients

    It’s a rite of passage — or probably should be — for adults upon reaching 50 years of age: Getting vaccinated for shingles.

    Currently, the two-dose Shingrix vaccine, which is the only shingles vaccine available in the US, is recommended for adults aged 50 years or older, as well as adults aged 19 years or older who are immunocompromised.

    The vaccine shouldn’t be a hard sell, given the available information about its effectiveness and the risks for shingles, John Pauk, MD, MPH, medical director of Infectious Diseases, Infection Prevention, and Antimicrobial Stewardship for Swedish Health Services and Caregiver Health for Providence Swedish in Seattle, said. “The most important step is remembering to make the time during medical visits to have the conversations as part of preventative care,” he said.

    The two-dose vaccine could also be more important for patients at risk for cardiovascular problems. Research released last month shows patients who get the vaccine have a 23% lower risk for all cardiovascular disease events, including stroke, heart failure, and coronary heart disease.

    Those benefits last for up to 8 years, researchers found, and the protective effect was particularly pronounced for men, people younger than 60 years, and those with unhealthy lifestyles, such as smoking, drinking alcohol, and being inactive.

    However, in a time of growing vaccine hesitancy, clinicians may worry they’ll begin encountering some reluctance among their patients to get the shingles vaccine.

    Elizabeth Mock, MD, MPH

    “It’s harder nowadays because there’s so much misinformation about vaccines,” Elizabeth Mock, MD, MPH, a member of the board of directors for the American Academy of Family Physicians, said. “People are more likely to get their medical information from TikTok than they are from their family physician. That’s a difficult thing to overcome.”

    Here’s what physicians and other providers may want to consider when speaking to their patients about the importance of the shingles vaccine.

    Why the Shingles Vaccine Matters

    Ask any clinician who’s cared for a patient with shingles if they’d get vaccinated for shingles themselves, and you’re likely to get a hearty “yes.”

    Ryan C. Maves, MD, professor of infectious disease and internal medicine at Wake Forest University School of Medicine, Winston-Salem, North Carolina, celebrated his own 50th birthday by calling to schedule his first dose of the shingles vaccine. “I’ve taken care of a lot of shingles over the years,” he said. “I don’t want shingles.”

    photo of Salisia Valentine
    Salisia Valentine, DNP, FNP-C, MSN, RN

    “It’s just miserable,” agreed Salisia Valentine, DNP, FNP-C, MSN, RN, vice president of Provider Services at American Family Care. “The ones who’ve had it are the ones saying, ‘Give me the vaccine. This is awful.’”

    A few points to discuss with patients about the vaccine:

    It Prevents Nerve Pain

    As a neurotropic virus, the varicella zoster virus (VZV) is infamous for causing postherpetic neuralgia (PHN). After the painful, itchy rash clears up, pain can linger in the same affected areas for months or, in some cases, years. Between 10% and 20% of patients with zoster develop PHN, and it can have a very serious impact on their lives, Pauk said.

    However, vaccination is considered more than 90% effective in preventing shingles and PHN in adults older than 50 years with healthy immune systems, according to the CDC.

    Treatments Are Only ‘Variably Effective’

    While many treatments can be used to manage PHN, there’s no standard treatment. Nonsteroidal anti-inflammatory drugs may help people with milder pain, and an antiseizure drug, such as gabapentin or pregabalin, may be more appropriate for managing more severe nerve pain. Even then, treatments are only “variably effective,” according to Judith O’Donnell, MD, chief of Infectious Diseases at Penn Presbyterian Medical Center and professor of infectious diseases at the Perelman School of Medicine at the University of Pennsylvania, Philadelphia.

    photo of Judith O Donnell
    Judith O’Donnell, MD

    “Some people do get reasonable pain control with them, but others do not, and you don’t know who those are going to be,” she said.

    Maximo Brito, MD, MPH, professor of medicine at the University of Illinois College of Medicine, Chicago, added, “There are treatments that are available, but I think prevention is much better than treatment.”

    It Can Reduce the Possibility of Herpes Zoster Ophthalmicus

    If the prospect of nerve pain isn’t enough to convince some patients of the benefits of getting vaccinated for shingles, the possibility of vision loss might be.

    The VZV can reactivate in the ophthalmic branch of the fifth cranial nerve, causing herpes zoster ophthalmicus, which may occur in as many as 10%-20% of herpes zoster cases. According to research, conjunctivitis seems to be the most common involvement, followed by keratitis and uveitis, but a small percentage of people may experience moderate or even severe vision loss, usually caused by corneal scarring.

    How to Bring Up the Issue

    O’Donnell suggests clinicians start talking to their patients at well visits before they reach their 50th birthday, when most people become eligible for the two-dose Shingrix vaccine. Then they can give reminders.

    It may also help to explain that almost everyone born before about 1980 is at risk for shingles because chickenpox was in such wide circulation during their childhood. That means the VZV is dormant in their bodies, waiting to be reactivated.

    “Even if we don’t know it, we were likely exposed to the chickenpox virus,” Mock said. “Some people might have been exposed to it and gotten the virus and never gotten sick from it.” 

    Clinicians must be prepared to respond to patients concerns and talk to them about the risk-benefit ratio of the shingles vaccine.

    “Take your time, show sympathy, listen, answer questions, and (don’t) get defensive,” Brito said.

    “If patients decline, keep the lines of communication open around vaccines, and continue to revisit their vaccination status,” O’Donnell said. “Be willing to talk through it and offer them vaccines even if they say no the first time.”

    photo of  Neha Vyas
    Neha Vyas, MD

    Neha Vyas, MD, a family medicine physician with Cleveland Clinic, Mayfield Heights, Ohio, said she would encourage other clinicians not to give up on patients who might decline the chance to get vaccinated. “If you keep talking, the next time they may agree,” Vyas said.

    Plus, “this is not something that you have to get yearly,” she added.

    Maves emphasized the importance of candor when discussing the shingles vaccine with patients, which includes being upfront about the possible side effects. The most common side effects tend to be injection site swelling and soreness, muscle pain, fatigue, and possibly headache, fever, and shivering.

    He often recommends that patients schedule their vaccines on a Friday or another day before an off day, just in case they do experience some fatigue and muscle pain. “Just be braced for it. Just be ready for it,” he tells them.

    Benefits Beyond Shingles Prevention?

    Eventually, clinicians may also be able to offer additional benefits of vaccination to their patients.

    Several recent studies have suggested that people may receive other benefits from getting vaccinated for shingles.

    For example, a recent study published in the European Heart Journal found an association between lower risks of overall cardiovascular events and live zoster vaccination. Meanwhile, the results of a recent study in JAMA that reviewed electronic health records in Australia suggested that herpes zoster vaccination may prevent or delay the onset of dementia. Another study, which was published in Nature, analyzed electronic health record data, this time in England and Wales, and also found that live-attenuated herpes zoster vaccination seemed to have a preventive effect for dementia.

    However, the live zoster vaccine is not available in the US, with Zostavax having been removed from the market in 2020.

    That doesn’t mean that people couldn’t potentially receive similar benefits from the recombinant vaccine that is available here. According to a retrospective cohort study published earlier in 2025 in Vaccine, the rate of dementia was significantly lower in individuals who had received two doses of the recombinant zoster vaccine.

    More research could be helpful to determine if patients who receive the two-dose Shingrix vaccine could receive other benefits. However, the primary reason to get the two doses of Shingrix, which is shingles prevention, is a worthwhile cause all by itself, Maves said.

    Continue Reading

  • PM stresses accelerated efforts to eradicate polio from Pakistan – Ptv.com.pk

    1. PM stresses accelerated efforts to eradicate polio from Pakistan  Ptv.com.pk
    2. New polio case from KP takes tally to 14  Dawn
    3. Why Pakistan is among last 2 countries where polio remains an endemic  The Indian Express
    4. Prime Minister Muhammad Shehbaz Sharif chairs a meeting of National Task Force on Eradication of Polio  Associated Press of Pakistan
    5. Pakistan thanks Saudi Arabia, pledges renewed anti-polio effort as cases hit 14  Arab News PK

    Continue Reading

  • The value of first trimester inflammatory indices in predicting the development of preeclampsia in the third trimester | BMC Pregnancy and Childbirth

    The value of first trimester inflammatory indices in predicting the development of preeclampsia in the third trimester | BMC Pregnancy and Childbirth

    Preeclampsia remains a leading cause of maternal and perinatal morbidity and mortality worldwide, and its multifactorial etiology continues to challenge early prediction strategies. In recent years, hematologic inflammatory markers derived from complete blood counts have garnered interest as accessible and cost-effective tools for identifying women at risk. In our study, several first-trimester inflammatory indices—including NLR, SII, SIRI, and AISI—were found to be significantly lower in the preeclampsia group compared to healthy controls. Notably, the lymphocyte-to-monocyte ratio (LMR) demonstrated the highest discriminatory capacity among the indices examined (AUC: 0.625), although overall predictive performance was modest.

    A retrospective case-control study conducted at a tertiary center in Türkiye involving 236 pregnant women evaluated platelet indices and inflammation markers in the context of preeclampsia. The study reported that platelet distribution width (PDW) levels were significantly elevated in both mild and severe preeclampsia cases, and a PDW threshold above 13.15 was predictive of adverse neonatal outcomes (AUC: 0.633). While our study did not include PDW in the analysis, the moderate predictive value reported in that study aligns with the diagnostic limitations observed in our findings, where even the best-performing index (LMR) showed only modest discriminatory capacity (AUC: 0.625). Together, these results underscore the ongoing need for more robust biomarkers or composite scoring systems to enhance early prediction of preeclampsia [8].

    A retrospective case-control study conducted in Türkiye in 2023 examined the predictive value of first-trimester hemogram parameters and platelet indices for preeclampsia. The study included 290 pregnant women—145 with preeclampsia and 145 normotensive controls—and found that platelet distribution width (PDW) and mean platelet volume (MPV) were significantly elevated in the preeclampsia group. These findings suggest that platelet activation may play an early role in the pathogenesis of the disease. While our study did not assess platelet-specific indices beyond PLR, both studies share the aim of identifying cost-effective, early biomarkers from routine blood tests. However, our findings emphasize reduced inflammatory indices in the preeclampsia group, whereas theirs focus on elevated platelet-based markers. This contrast underscores the need for integrative biomarker models that encompass both inflammatory and thrombocytic pathways to enhance early prediction [9].

    In a large retrospective cohort study from Türkiye, Özkan et al. assessed the predictive value of first-trimester inflammatory indices—specifically SII, SIRI, and AISI—in 435 pregnant women. They reported significantly higher values of SIRI and AISI in women who developed preeclampsia, with AISI showing the strongest association. These findings contrast with our study, in which all three indices were significantly lower in the preeclampsia group. Although these markers were statistically significant in univariate analysis, none retained predictive power in multivariate regression or ROC analysis. This discrepancy may be attributed to differences in population characteristics, clinical definitions, or the impact of unidentified confounding variables. It also underscores the need for cautious interpretation of hematologic markers when used in isolation [10].

    A cross-sectional study conducted in China established gestational age-specific reference ranges for key inflammatory indices, including NLR, PLR, LMR, and SII, in a cohort of healthy pregnant women. Their findings revealed that even in uncomplicated pregnancies, markers such as NLR and SII exhibited higher median values than those reported in our study population. This observation emphasizes that baseline inflammatory activity may differ significantly across ethnic and geographic populations. Moreover, it suggests that low levels of certain indices, such as SII and NLR in our preeclampsia group, do not necessarily indicate the absence of pathology, but may instead reflect variations in immunological adaptation or regulatory mechanisms during early pregnancy. These differences underscore the necessity of population-specific reference ranges and caution against universal application of biomarker cut-off values [11].

    A case-control study conducted in a tertiary hospital in Türkiye in 2023 evaluated the predictive role of first-trimester eosinophil counts and eosinophil-derived hematological indices in the development of preeclampsia. The study included 171 pregnant women (75 with preeclampsia and 96 healthy controls). It demonstrated that decreased eosinophil counts and related indices were significantly associated with preeclampsia, suggesting that these markers may serve as accessible early predictors of the disease. Similar to our study, this research emphasized the utility of routine hematologic parameters in early gestation for risk prediction. However, while that study focused specifically on eosinophil-related markers, our investigation assessed a broader set of inflammation-based indices, including NLR, PLR, SII, and LMR. Notably, although both studies support the early predictive potential of CBC-based markers, our findings revealed limited predictive strength for most indices, with only LMR showing moderate discriminative capacity (AUC: 0.625). These differences may be attributed to the distinct cell types evaluated or population-specific characteristics [12].

    Finally, Özkan et al. (2024) also investigated these indices in a case-control study on HELLP syndrome, a severe variant of preeclampsia, in Türkiye. They found significantly elevated values for SII, SIRI, and AISI in patients with HELLP compared to controls. While our study excluded HELLP cases, the stark elevation in these markers in severe hypertensive states underscores the severity-dependent nature of systemic inflammation in pregnancy complications and supports the pathophysiological basis for using such indices [13].

    In summary, the literature consistently demonstrates a link between elevated inflammatory markers and preeclampsia, particularly in its severe forms and later stages of pregnancy. Our study contributes to this body of knowledge by highlighting the potential for suppressed inflammatory activity in early pregnancy among women who develop preeclampsia. These findings underscore the importance of longitudinal studies to capture the dynamic changes in inflammatory markers throughout gestation and their implications for early diagnosis and management of preeclampsia.

    This study has several limitations. First, its retrospective design may introduce selection and information biases. Second, although patients with known inflammatory or chronic conditions were excluded, subclinical inflammation could not be ruled out. Third, the study did not stratify patients into early- and late-onset preeclampsia, which may represent distinct clinical entities. Lastly, the predictive power of the evaluated indices was limited in multivariate and ROC analyses, suggesting that these markers should be interpreted in conjunction with other clinical factors.

    Continue Reading